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Metabolic syndrome is defined as a cluster of multiple risk factors, including central obesity, 
dyslipidemia, hypertension, and impaired glucose tolerance, that increase cardiovascular disease 
morbidity and mortality.  Genetic factors are important in the development of metabolic 
syndrome, as are environmental factors.  However, the genetic background of metabolic 
syndrome is not yet fully clarified.  There is evidence that obesity and obesity-related 
phenotypes are associated with variations in several genes, including NEGR1, SEC16B, 
TMEM18, ETV5, GNPDA2, BDNF, MTCH2, SH2B1, FTO, MAF, MC4R, KCTD15, SCG3, 
MTMR9, TFAP2B, MSRA, LYPLAL1, GCKR, and FADS1.  To investigate the relationship 
between metabolic syndrome and variations in these genes in the Japanese population, we 
genotyped 33 single-nucleotide polymorphisms (SNPs) in 19 genes from 1096 patients with 
metabolic syndrome and 581 control individuals who had no risk factors for metabolic 
syndrome.  Four SNPs in the FTO gene were significantly related to metabolic syndrome: 
rs9939609 (P = 0.00013), rs8050136 (P = 0.00011), rs1558902 (P = 6.6 × 10-5), and rs1421085 
(P = 7.4 × 10-5).  rs3764220 in the SCG3 gene (P = 0.0010) and rs2293855 in the MTMR9 gene 
(P = 0.0015) were also significantly associated with metabolic syndrome.  SNPs in the FTO, 
SCG3, and MTMR9 genes had no SNP × SNP epistatic effects on metabolic syndrome.  Our 
4 
 
data suggest that genetic variations in the FTO, SCG3, and MTMR9 genes independently 
influence the risk of metabolic syndrome. 
 





Metabolic syndrome is a common clinical phenotype that is concurrent with metabolic 
abnormalities, including central obesity, glucose intolerance, dyslipidemia, and hypertension.1  
Several different definitions of the syndrome exist2 and there are still debates on the adequacy of 
the concept; however, metabolic syndrome has attracted considerable interest.  Although the 
pathogenesis of metabolic syndrome is not fully understood, the predominant underlying risk 
factor is considered to be central obesity due to an atherogenic diet and physical inactivity in the 
presence of some genetic background.2, 3  Adipose tissue, especially visceral fat, secretes 
various adipocytokines.  An increase in adipose tissue mass leads to an alteration in the plasma 
levels of adipocytokines, resulting in the development of dyslipidemia, hypertension, and 
insulin resistance.3, 4 
Results from studies using twins and families have suggested that genetic and 
environmental factors contribute to the clustering of metabolic abnormalities in various ethnic 
groups.5-10  We determined in a previous study that 4 single-nucleotide polymorphisms (SNPs) 
(rs2294901, rs6133922, rs6077785, and rs6108572) in the McKusick–Kaufman syndrome 
(MKKS) gene were significantly associated with metabolic syndrome in the Japanese 
population11 by screening SNPs in 85 obesity-related genes that had been reported as of 2005.12  
We carried out a large-scale case-control association study and found that secretogranin III 
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(SCG3)13 and myotubularin-related protein 9 (MTMR9)14 conferred susceptibility to the obesity 
phenotype in the Japanese population.  Recent genome-wide association studies revealed the 
SNPs associated with obesity and fat distribution (waist circumference and waist to hip 
ratio).15-19  We confirmed that some of these SNPs are also associated with obesity and visceral 
fat area as determined by computed tomography (CT) in the Japanese population.20-22   
In this study, we investigated the association between metabolic syndrome and 33 
SNPs related to obesity and the obesity-related phenotype.  We found that SNPs in the fat mass 
and obesity associated (FTO), SCG3, and MTMR9 genes are associated with metabolic 
syndrome. 
 
MATERIALS AND METHODS 
Study subjects 
The sample size of the group of Japanese subjects with metabolic syndrome was 1096 (male to 
female ratio, 594:502; age, 53.8 ± 12.5 years).  The sample size of the group of Japanese 
controls was 581 (male to female ratio, 182:399; age, 47.2 ± 14.8 years).  Metabolic syndrome 
was diagnosed as reported previously.11, 23  In brief, metabolic syndrome is defined by the 
presence of 2 or more metabolic abnormalities in addition to obesity (body mass index [BMI] > 
25 kg m-2).  The metabolic abnormalities were as follows: (1) triglyceride level ≥ 150 mg per 
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100 ml and/or high-density lipoprotein cholesterol level < 40 mg per 100 ml, or under treatment 
for this type of dyslipidemia; (2) systolic blood pressure ≥ 130 mm Hg and/or diastolic blood 
pressure blood pressure ≥ 85 mm Hg, or under treatment for hypertension; and (3) fasting 
glucose level ≥ 110 mg per 100 ml, or under treatment for diabetes.  The control group was 
consisted of the subjects who were not obese (BMI < 25 kg m-2) and who exhibited none of the 
metabolic abnormalities described above.  Clinical characteristics of subjects are summarized 
in Table 1.  Subjects with metabolic syndrome were recruited from outpatient clinics.  Control 
subjects were selected from non-obese Japanese volunteers who had undergone a medical 
examination for common disease screening.  Written informed consent was obtained from each 
subject, and the protocol was approved by the ethics committee of each institution and by that of 
Kyoto University. 
DNA preparation and SNP genotyping 
Using Genomix (Talent Srl, Trieste, Italy), genomic DNA was extracted from blood samples 
collected from each subject.  We constructed Invader probes (Third Wave Technologies, 
Madison, WI, USA) for rs3101336, rs2568958, and rs2815752 in the neuronal growth regulator 
1 (NEGR1) gene; rs10913469 in the SEC16 homolog B (SEC16B) gene; rs6548238 and 
rs7561317 in the transmembrane protein 18 (TMEM18) gene; rs7647305 in the ets variant 5 
(ETV5) gene; rs10938397 in the glucosamine-6-phosphate deaminase 2 (GNPDA2) gene; 
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rs6265 and rs925946 in the brain-derived neurotrophic factor (BDNF) gene; rs10838738 in the 
mitochondrial carrier homolog 2 (MTCH2) gene; rs7498665 in the SH2B adaptor protein 1 
(SH2B1) gene; rs9939609, rs8050136, rs6499640, rs1121980, rs1558902, and rs1421085 in the 
FTO gene; rs1424233 in the v-maf musculo-aponeurotic fibrosarcoma oncogene homolog 
(MAF) gene; rs17782313, rs12970134, rs489693, and rs17700144 in the melanocortin 4 
receptor (MC4R) gene; rs29941 and rs11084753 in the potassium channel tetramerisation 
domain containing 15 (KCTD15) gene; rs3764220 in the SCG3 gene; rs2293855 in the MTMR9 
gene; rs987237 in the transcription factor AP-2 (TFAP2B) gene; rs7826222 in the methionine 
sulfoxide reductase A (MSRA) gene; rs2605100 in the lysophospholipase-like-1 (LYPLAL1) 
gene; rs780094 and rs1260326 in the glucokinase regulator (GCKR) gene; and rs174547 in the 
fatty acid desaturase 1 (FADS1) gene.  The SNPs were genotyped using Invader assays as 
previously described.24  The success rate of these assays was > 99.0%. 
Statistical analysis 
For the additive model, we coded genotypes as 0, 1, or 2, depending on the number of copies of 
the risk alleles.  For the dominant model, homozygosity and heterozygosity with the risk allele 
were coded as 1 and the other was coded as 0.  For the recessive model, homozygosity with the 
risk allele was coded as 1 and others were coded as 0.  Additive, dominant, and recessive 
models were chosen for each SNP, according to data from the previous reports13-22.  Odds 
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ratios (ORs) and P-values adjusted for age and gender were calculated using multiple logistic 
regression analysis with genotypes, age, and gender as the independent variables.  The 
Hardy–Weinberg equilibrium was assessed using the χ2-test.25  Simple comparison of the 
clinical data between case and control groups was carried out using the Mann–Whitney U-test.  
To test SNP × SNP epistasis for case–control population–based samples, we used the logistic 
regression model for each SNP1 and SNP2, and fits the model in the form of 
Y=0+1×SNP1+2×SNP2+3×SNP1×SNP2+4×age+5×gender.  Statistical analysis was 
performed using the software R (http://www.r-project.org/).  P–values were corrected by 
Bonferroni adjustment and P < 0.00152 (0.05/33) was considered significant.  
We examined the power (α = 0.00152) of the test for 1096 cases and 581 controls 
using GDesignPlus (StaGen Co Ltd., Tokyo, Japan).  We considered the controls of 4 different 
levels of minor allele frequencies (MAF) (0.1–0.4) and 4 different levels of the ORs (1.2–1.5).  
Obtained power was indicated in Supplementary Table 1. 
 
RESULTS 
We used measurements of BMI (>25 kg m-2) instead of waist circumference, as there are still 
debates on the criteria for waist circumference, especially in Japanese women.  The prevalence 
of metabolic syndrome increased with subject age and has been previously reported to be 
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approximately 6–7 times higher in men than in women in Japan.23  Among our subjects, the 
ratio of men to women and the average age were both significantly higher in the case group than 
in the control group (Table 1).  To adjust for the effects of age and gender, logistic regression 
analysis was performed.  The most significant associations were observed for rs1558902 (P = 
6.6 × 10-5, allele-specific OR (95% confidence interval (CI) adjusted for age and gender) = 1.47 
(1.22–1.78)) and rs1421085 (P = 7.4 × 10-5, allele-specific OR (95% CI adjusted for age and 
gender) = 1.47 (1.21–1.77)) in the FTO gene (Table 2).  These 2 SNPs were previously 
reported as variations associated with waist circumference18, 19 and associated with visceral fat 
area as determined by CT.22  Two other SNPs (rs9939609 and rs8050136) in the FTO gene 
were also significantly associated with metabolic syndrome even when the conservative 
Bonferroni’s correction was applied (P < 0.00152).  Significant associations were also 
observed between metabolic syndrome and rs3764220 in the SCG3 gene (P = 0.0010) and 
rs2293855 in the MTMR9 gene (P = 0.00146).  SNPs, rs6548238 and rs7561317 in the 
TMEM18 gene, rs7498665 in the SH2B1 gene, and rs1121980 in the FTO gene, were marginally 
associated with metabolic syndrome (P < 0.05).  SNP rs10838738 in the MTCH2 gene was 
also marginally associated with metabolic syndrome, although presence of the G-allele, which is 
a risk allele for obesity,15, 16, 21 was associated with a reduced risk of metabolic syndrome.  
Other SNPs did not show any significant associations with metabolic syndrome.  The lack of 
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significant association of these SNPs is most likely due to the relatively lower power of this 
study (Supplementary table 1).  All SNPs were in Hardy–Weinberg equilibrium (P > 0.05), 
with the exception of rs6499640 (P = 0.0099) and rs1424233 (P = 0.0034) in the case group and 
rs3764220 in the control subjects (P = 0.0018). 
 Since 6 SNPs were significantly associated with metabolic syndrome, we tested SNP × 
SNP epistasis.  Four SNPs in the FTO gene were in a linkage disequilibrium (LD) (r2 > 0.97), 
thus, pair of these SNPs were not analyzed.  Any pairs of SNPs did not show significant 
epistatic effect on metabolic syndrome (Table 3).  We performed the multiple logistic 
regression analysis with 3 genotypes (rs1558902, rs3764220, and rs2293855), age, and gender 
as the independent variables and found that effects of these SNPs in the three genes on 
metabolic syndrome were additive: rs1558902 (additive model), P = 4.1×10-5, OR (95% CI) = 
1.50 (1.23 – 1.81); rs3764220 (dominant model), P = 0.00018, OR (95% CI) = 4.77 (2.11 – 
10.79); rs2293855 (recessive model), P = 0.00090, OR (95% CI) = 1.46 (1.17 – 1.82).  Similar 
results were obtained using rs9939609, rs8050136, and rs1421085, instead of rs1558902. 
 Next, we examined the effects of significant SNPs on each metabolic disorder 
(dyslipidemia, hypertension, and impaired fasting glucose).  SNPs (rs9939609, rs8050136, 
rs1558902, and rs1421085) in the FTO gene were significantly associated with dyslipidemia, 
hypertension, and impaired fasting glucose (Table 4).  rs2293855 in the MTMR9 gene was 
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significantly associated with hypertension and impaired fasting glucose, and was marginally 
associated with dyslipidemia.  rs3764220 in the SCG3 gene was marginally associated with all 




The SNPs that were most significantly associated with metabolic syndrome (rs1558902 and 
rs1421085) exist in the FTO gene.  Visceral fat accumulation is the most predominant factor 
for the development of metabolic syndrome.  SNPs (rs1558902 and rs1421085) were reported 
to be associated with waist circumference and visceral fat area as measured by CT.18, 19, 22  
SNPs (rs9939609, rs8050136, rs1558902 and rs1421085) were also associated with obesity and 
type 2 diabetes.15-17  We have previously reported that rs3764220 in the SCG3 gene was 
associated with obesity and subcutaneous fat area as measured by CT13 and that rs2293855 in 
the MTMR9 gene was associated with obesity and hypertension.14  Therefore, it is likely that 
rs9939609, rs8050136, rs1558902 and rs1421085 in the FTO, rs3764220 in the SCG3 and 
rs2293855 in the MTMR9 genes would be susceptible for metabolic syndrome.  Epistasis, or 
gene–gene interaction, has recently received much attention in human genetics.26  In this study, 




In the simulation study, the power of this test was 0.317 in the following condition; the 
sizes of the case and the control groups are 1096 and 581, respectively, OR is 1.4, risk allele 
frequency is 0.2 and the model of inheritance is additive.  Therefore, further studies would be 
necessary to elucidate the association between SNPs and metabolic syndrome. 
SNPs (rs780094 and rs1260326) in the GCKR gene were previously reported to be 
associated with metabolic disorders27-29; however, the present study did not show the association 
with metabolic syndrome.  The C-allele of rs780094 was reported to be associated with 
increased fasting plasma glucose and lower triglyceride levels.  The risk allele of rs780094 had 
an antagonistic affect on plasma glucose and triglycerides levels.  SNP rs174547 in the FADS1 
gene, which is in almost complete linkage disequilibrium with rs174550, is associated with 
dyslipidemia and type 2 diabetes.28, 30  Similar to rs780094, the effects of the risk allele of 
rs174547 on type 2 diabetes, hypertension, and dyslipidemia are not the same.  Thus, rs780094 
and rs174550 are not likely to be important in the development of metabolic syndrome. 
SNPs (rs6548238 and rs7561317) in the TMEM18 gene were marginally associated 
with metabolic syndrome.  We have reported that these SNPs are associated with obesity.21  
Takeuchi et al. reported that rs48454344, which is in almost complete linkage disequilibrium 
with rs6548238 and rs7561317,21 was associated with BMI and type 2 diabetes.31  Therefore, 
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rs6548238 and rs7561317 in the TMEM18 gene might be susceptible for the development of 
metabolic syndrome. 
The G-allele of rs10838738 in the MTCH2 gene, which is a risk allele for obesity,16 
reduced the risk of metabolic syndrome.  Takeuchi et al. reported that the G-allele is a risk 
factor for obesity and is protective for type 2 diabetes.31  Although further investigations would 
be necessary, there is a possibility that there are some variations that are specifically associated 
with components of metabolic syndrome, apart from obesity. 
 Our approach effectively indicated that SNPs in the FTO, SCG3, and MTMR9 genes 
are associated with metabolic syndrome in the Japanese population, in addition to the previously 
reported SNPs in the MKKS gene.  SNPs in the FTO, SCG3, and MTMR9 genes had no SNP × 
SNP epistatic effects on metabolic syndrome.  Since metabolic syndrome is a complex concept 
and the criteria are still controversial, further investigations are necessary to elucidate the roles 
of SNPs in the MKKS, FTO, SCG3, and MTMR9 genes in the development of metabolic 
syndrome. 
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Table 1  Clinical characteristics of the subjects 
 
Case Control P-value 
Gender（men/women） 594/502 182/399 <0.0001 
Age (years) 53.8 ± 12.5 47.2 ± 14.8 <0.0001 
Body mass index (kg m-2) 32.0 ± 5.2 21.4 ± 2.1 <0.0001 
Plasma glucose (mg per 100 ml) 131.9 ± 45.1 90.9 ± 7.7 <0.0001 
Triglycerides (mg per 100 ml) 184.0 ± 145.3 76.0 ± 28.8 <0.0001 
High-density lipoprotein cholesterol (mg per 100 ml) 51.3 ± 18.0 67.3 ± 14.0 <0.0001 
Systolic blood pressure (mm Hg) 139.9 ± 17.0 111.1 ± 10.2 <0.0001 
Diastolic blood pressure (mm Hg) 85.3 ± 12.2 69.4 ± 7.5 <0.0001 
    
Prevalence of metabolic disease 
   
 Dyslipidemia 858 (78%) 0 
 
 Hypertension 974 (89%) 0 
 
 Impaired fasting glucose 770 (70%) 0 
 
    
No. of subjects under treatment 
   
 Dyslipidemia 319 0 
 
 Hypertension 466 0 
 
 Diabetes 379 0 
 
Data are shown as the mean ± s.d.  Men/women ratio was analyzed by the χ2-test.  P-values for quantitative traits were analyzed using the 
Mann–Whitney U-test. 
Table 2  Genotype and association tests 
 Nearby Allele1/ Risk Genotype    
SNP ID gene Allele2 allele Case Control Model P-value OR (95% CI) 
rs3101336 NEGR1 A/G G 4/153/938 1/88/492 a 0.55 1.09 (0.82 – 1.46) 
rs2568958 NEGR1 A/G A 932/154/4 490/88/1 a 0.60 1.08 (0.81 – 1.44) 
rs2815752 NEGR1 A/G A 938/154/4 492/88/1 a 0.58 1.09 (0.81 – 1.45) 
rs10913469 SEC16B T/C C 596/430/69 331/224/26 a 0.054 1.19 (1.00 – 1.43) 
rs6548238 TMEM18 T/C C 8/169/919 7/101/473 a 0.037 1.32 (1.02 – 1.71) 
rs7561317 TMEM18 G/A G 917/171/8 472/102/7 a 0.037 1.32 (1.02 – 1.71) 
rs7647305 ETV5 C/T C 1015/77/0 537/39/1 a 0.57 1.13 (0.75 – 1.70) 
rs10938397 GNPDA2 A/G G 513/470/111 289/235/55 a 0.37 1.08( 0.92 – 1.27) 
rs6265 BDNF A/G G 182/522/388 100/283/196 a 0.29 1.09 (0.93 – 1.26) 
rs925946 BDNF T/G T 2/74/1020 0/44/537 a 0.75 0.94 (0.63 – 1.40) 
rs10838738 MTCH2 G/A G 95/437/564 67/234/277 a 0.023 0.83 (0.71 – 0.98) 
rs7498665 SH2B1 G/A G 30/280/784 9/133/439 a 0.045 1.25( 1.01 – 1.55) 
rs9939609 FTO T/A A 650/379/65 389/170/20 a 0.00013 1.45 (1.20 – 1.75) 
rs8050136 FTO C/A A 650/377/65 389/171/19 a 0.00011 1.45 (1.20 – 1.76) 
rs6499640 FTO A/G A 33/248/814 9/134/438 a 0.35 1.11 (0.89 – 1.37) 
rs1121980 FTO A/G A 74/404/614 25/196/357 a 0.0028 1.32 (1.10 – 1.58) 
rs1558902 FTO A/T A 63/381/648 19/170/391 a 6.6×10-5 1.47 (1.22 – 1.78) 
rs1421085 FTO C/T C 63/380/648 19/170/390 a 7.4×10-5 1.47 (1.21 – 1.78) 
rs1424233 MAF C/G C 644/368/83 329/211/40 a 0.63 1.04 (0.88 – 1.23) 
rs17782313 MC4R T/C C 638/392/66 348/200/33 a 0.25 1.11 (0.93 – 1.32) 
rs12970134 MC4R A/G A 21/304/762 16/157/404 a 0.68 1.04 (0.85 – 1.28) 
rs489693 MC4R C/A A 682/367/45 365/191/24 a 0.43 1.08 (0.89 – 1.30) 
rs17700144 MC4R A/G A 2/67/1025 1/31/546 a 0.21 1.32 (0.85 – 2.05) 
rs29941 KCTD15 T/C C 672/378/45 349/209/22 a 0.62 1.05 (0.87 – 1.26) 
rs11084753 KCTD15 G/A G 96/472/528 56/243/282 a 0.60 1.04 (0.89 – 1.23) 
rs3764220 SCG3 A/G A 844/240/11 438/120/20 d 0.0010 3.74 (1.70 – 8.23) 
rs2293855 MTMR9 A/G A 482/466/146 215/282/83 r 0.0015 1.43 (1.15 – 1.78) 
rs987237 TFAP2B A/G G 664/382/48 363/188/27 a 0.48 1.07 (0.89 – 1.28) 
rs7826222 MSRA G/C C 423/511/162 232/269/79 a 0.66 1.04 (0.89 – 1.21) 
rs2605100 LYPLAL1 A/G G 39/315/740 19/159/399 a 0.67 0.96 (0.79 – 1.17) 
rs780094 GCKR T/C C 213/510/368 124/287/169 a 0.17 1.11 (0.96 – 1.28) 
rs1260326 GCKR T/C T 364/519/211 160/297/124 a 0.072 1.15 (0.99 – 1.33) 
rs174547 FADS1 T/C C 426/537/133 232/262/87 a 0.48 0.95 (0.81 – 1.11) 
The OR for each SNP was adjusted simultaneously for age and gender. 
Table 3  Results for SNP pairs for epistasis in case–control analysis 
SNP1 SNP2 OR (95% CI) Epistasis P-value 
rs2293855 rs3764220 0.07 (0.01 – 0.70) 0.023 
rs2293855 rs1421085 0.80 (0.55 – 1.18) 0.27 
rs2293855 rs1558902 0.81 (0.55 – 1.19) 0.29 
rs2293855 rs8050136 0.84 (0.57 – 1.24) 0.38 
rs3764220 rs9939609 0.82 (0.56 – 1.21) 0.32 
rs3764220 rs1421085 1.60 (0.44 – 5.82) 0.48 
rs3764220 rs1558902 1.60 (0.44 – 5.84) 0.47 
rs3764220 rs8050136 1.58 (0.43 – 5.74) 0.49 
rs3764220 rs9939609 1.57 (0.43 – 5.71) 0.49 
 
Table 4  Genotype and association tests of dyslipidemia, hypertension, and impaired fasting glucose 
 Control Dyslipidemia (n=858) Hypertension (n=974) Impaired fasting glucose (n=770) 
 genotype Genotype P-value OR (95% CI) Genotype P-value OR (95% CI) Genotype P-value OR (95% CI) 
rs9939609 389/170/20 511/297/48 0.00051 1.42 (1.17 – 1.73) 575/342/57 9.5×10-5 1.47 (1.21 – 1.79) 458/266/44 0.00024 1.46 (1.19 – 1.79) 
rs8050136 389/171/19 511/295/48 0.00045 1.43 (1.17 – 1.74) 575/339/57 8.9×10-5 1.48 (1.22 – 1.80) 458/265/44 0.00020 1.47 (1.20 – 1.80) 
rs1558902 19/170/391 47/298/510 0.00024 1.45 (1.19 – 1.77) 55/344/573 4.8×10-5 1.50 (1.23 – 1.83) 43/268/456 0.00011 1.49 (1.22 – 1.83) 
rs1421085 19/170/390 47/297/509 0.00026 1.45 (1.19 – 1.77) 55/343/573 5.4×10-5 1.50 (1.23 – 1.82) 43/267/456 0.00012 1.49 (1.22 – 1.83) 
rs3764220 438/120/20 658/190/9 0.0042 3.37 (1.47 – 7.76) 752/210/11 0.0028 3.34 (1.52 – 7.38) 592/170/8 0.0026 3.81 (1.60 – 9.10) 
rs2293855 215/282/83 366/372/118 0.0098 1.35 (1.08 – 1.70) 430/415/127 0.00098 1.46 (1.17 – 1.83) 351/315/104 0.00039 1.53 (1.21 – 1.93) 
The OR for each SNP was adjusted simultaneously for age and gender. 
Supplementary Table 1  The power of the test 
  OR   
MAF 1.2 1.3 1.4 1.5 
0.1 0.017 0.051 0.123 0.240 
0.2 0.040 0.136 0.317 0.546 
0.3 0.062 0.211 0.457 0.708 
0.4 0.076 0.256 0.527 0.771 
0.5 0.081 0.267 0.538 0.776 
 
